Printer Friendly

SCIENTISTS REPORT USE OF ADVANCED TISSUE SCIENCES' TECHNOLOGY FOR CARTILAGE AND BONE GROWTH

 LA JOLLA, Calif., Feb. 18 /PRNewswire/ -- Scientists reported today the successful in vitro growth of cartilage and bone tissues using a proprietary tissue engineering technology developed by Advanced Tissue Sciences Inc. (NASDQ-NMS: ATIS). These results were reported in five separate presentations at the annual meeting of the Orthopedic Research Society, San Francisco.
 "These results further validate the utility of our tissue engineering process for generating cartilage and bone tissues that are consistent with human tissue," said Gail K. Naughton, Ph.D., Advanced Tissue Sciences' executive vice president and chief operating officer. "The data represent a significant advancement in our understanding of cartilage and bone tissue growth and the implications of these tissues for reconstructive and orthopedic surgery."
 Scientists reported the in vitro growth of a composite bone and cartilage tissue using Advanced Tissue Sciences' proprietary technology. They also reported that three-dimensional bone and cartilage tissues grown in vitro secreted extracellular matrix proteins and retained biomechanical properties analogous to those of the tissues native to the human body. In addition, tissues grown in vitro and subsequently transplanted into cranial defects in animals repaired damaged tissue.
 The availability of tissue engineered cartilage and bone could address the needs of many patients. Engineered cartilage tissue could be used for joint resurfacing and reconstructive surgery. Patients could benefit from engineered bone tissue, used alone or as a composite with cartilage, for various orthopedic applications.
 Advanced Tissue Sciences Inc. is a tissue engineering company engaged in the growth of human tissues and organs for potential therapeutic and laboratory applications. Using its proprietary three-dimensional culture system, the company has successfully replicated a variety of human tissues including skin, cartilage, oral mucosa, bone marrow and liver.
 -0- 2/18/93
 /CONTACT: Janet M. Wahl, director, corporate communications of Advanced Tissue Sciences, 619-450-5737/
 (ATIS)


CO: Advanced Tissue Sciences Inc. ST: California IN: MTC SU:

KJ-MS -- SD004 -- 7938 02/18/93 13:31 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 18, 1993
Words:315
Previous Article:CAMPBELL CEO SAYS CHANGING WORLD REQUIRES FLEXIBLE LEADERSHIP
Next Article:BOEING FORECASTS EMPLOYMENT REDUCTIONS
Topics:


Related Articles
ADVANCED TISSUE SCIENCES AND NEOMORPHICS SIGN DEFINITIVE ACQUISITION AGREEMENT
ADVANCED TISSUE SCIENCES AND KIRIN ENTER INTO AGREEMENT
ADVANCED TISSUE SCIENCES RECEIVES FDA APPROVAL TO BEGIN CLINICAL TRIALS OF DERMAGRAFT-TC
ADVANCED TISSUE SCIENCES' DERMAGRAFT-TC PILOT DATA PRESENTED
ADVANCED TISSUE SCIENCES RECEIVES APPROVAL TO BEGIN PIVOTAL CLINICAL TRIAL OF DERMAGRAFT(TM) FOR DIABETIC ULCERS
ADVANCED TISSUE SCIENCES REPORTS ALLOWANCE OF EUROPEAN PATENT
Osiris Therapeutics Completes License and Research Agreement with Northwestern University for a Novel Cartilage-Forming Molecule
Advanced Tissue Sciences Announces Submission of Premarket Approval Application for Dermagraft(R) in Diabetic Foot Ulcers
Advanced Tissue Sciences Announces Submission of Premarket Approval Application for Dermagraft(R) in Diabetic Foot Ulcers
Artecel Sciences Announces in Vitro Proof-of-Principle Studies Supporting the Utility of Adipose Tissue as a Source of Differentiated Human Cells.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters